DNA-PK controls cyclic dinucleotide-associated type I Interferon responses

clara taffoni,isabelle k vila,jane jardine,moritz schussler,Joe McKellar,Morgane Chemarin,Joanna Re,Yasmine Messaout-Nacer,Insaf El Mansouri,George Panagiotis Chrousos,Nicolas Bidere,Karim Majzoub,Dimitrios Vlachakis,Nadine Laguette

DOI: https://doi.org/10.1101/2024.09.17.613246

2024-09-20

Abstract:Cytosolic dsDNAs are potent immune-stimulatory molecules that trigger inflammation in several human pathologies. A major pathway for the detection of cytosolic dsDNA relies on the cyclic GMP-AMP (cGAMP) synthase (cGAS) that produces the 2′3′-cGAMP cyclic dinucleotide (CDN) for activation of the Stimulator of Interferon Genes (STING) adaptor protein that subsequently drives type I Interferon (IFN) responses. Here, we investigated the mechanism regulating intracellular 2′3′-cGAMP levels. We show that the DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a major player in the repair of double-strand breaks, directly regulates intracellular levels of 2′3′-cGAMP, thereby reducing STING activation. We describe that the binding of 2′3′-cGAMP to DNA-PKcs occurs in its catalytic cleft, impeding its kinase function. Contrary to other CDN regulatory mechanisms that have been shown to primarily regulate extracellular 2′3′-cGAMP, we show that DNA-PKcs also interacts with the 3′3′-cGAMP bacterial CDN, limiting its capacity to activate STING signaling. Furthermore, we found that DNA-PKcs decreases the potency of pharmacological STING activators. As STING is a major target for therapeutic interventions aiming to boost inflammatory responses in immunosuppressed contexts , our data bear important implications for drug development and deepens our understanding of inflammatory regulation in response to CDNs.

Immunology